Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors

Histology and Histopathology

Volumn 21, Issue 4-6, 2006, Pages 341-347

  Zagorianakou, N ^a   Stefanou, D ^a   Makrydimas, G ^a   Zagorianakou, P ^a   Briasoulis, E ^a   Karavasillis, V ^a   Pavlidis, N ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Metallothionein (MT); Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; METALLOTHIONEIN; PROTEIN P53; TUMOR MARKER;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR GROWTH; ADOLESCENT; ADULT; AGED; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; CYSTADENOMA; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOTHIONEIN; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644844909     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anstey A., Marks R. and Long C. (1996). In vivo photoindaction of metallothionein in human skin by ultraviolet-irradiation. J. Pathol. 136, 94-100.
2. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W. and Hamilton T.C. (1998). The biology of ovarian cancer. Semin. Oncol. 25, 281-304.
3. Bremmer I. (1991). Significance of metallothionein. Methods Enzymol 205, 25.
4. Brenner I. and J.H. Beattie. (1990). Metallothionein and the trace metal. Annu. Rev. Nutr. 10.
5. Cai L., Satoh M., Toyama C. and Cherian M.G. (1999). Metallothionein in radiation exposure: its induction and protective role. Toxicology 15, 85-89.
6. Cherian M., Jayasurya A. and Bay B.H. (2003). Metallothioneins in human tumors and potential roles in carcinogenesis. Mut. Res. 533, 201-209.
7. Dziegiel P., Fongocy J., Sudar E., Surowiak P., Kornafel J. and Zebel M. (2003). Prognostic significance of metallothionein expression in correlation with ki-67 expression in adenocarcinoma of large intestine. Histol. Histopathol. 18, 401-407.
8. Fan L.Z. and Cherian M.G. (2002). Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br. J. Cancer 87, 1019-1926.
9. Germain I., Tetu B., Brisson J., Mondor M. and Cherian M.G. (1996). Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int. J. Gynecol. Pathol. 15, 54-62.
10. Hamer D.H. (1986). Metallothionein. Annu. Rev. Biochem. 55, 913-951.
11. Haq F., Mahoney M. and Koropatnick J. (2003). Signaling events for metallothionein iduction. Mut. Res. 533, 211-226.
12. Hengstler J.G., Pilch H., Schimdt M., Dahlenburg H., Sagemuller J., Sciffer I., Oesch F., Knapstein P.G., Kaina B. and Tanner B. (2001). Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int. J. Cancer (Pred Oncol). 95, 121-127.
13. Ioachim E., Assimakopoulos D., Peschos D., Zissi A., Skevas A. and Agnantis N.J. (1999). Immunohistochemical expression of metallothionein in benign, premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nucleus antigen. Pathol. Res. Pract. 195, 809-814.
14. Ioachim E., Charchanti A., Stavropoulos N., Athanassion E., Michael M. and Agnantis N.J. (2001). Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53 and proliferation induces. Anticancer Res. 21, 1757-1761.
15. Jasani B. and Schimid K.W. (1997). Significance of metallothionein overexpression in human tumors. Histopathology 31, 211-214.
16. Johnston S.R.D. and Gore M.E. (2001). Phase II studies in ovarian cancer. Eur. J. Cancer. 37, S8-S14.
17. Joseph M.G., Banerjee D., Kocha W., Feld R., Stitt L.W. and Cherian M.G. (2001). Metallothionein expression in patients with small cell carcinoma of the lung. Correlation with other molecular markers and clinical out-come. Cancer 92, 836-842.
18. Ktsujikawa Suzuki N. and Sagawa K. (1994). Induction and subcellular localization of metaliothionein in regenerating rat liver. Eur. J. Cell Biol. 63, 240-6.
19. Kurman R.J. (1994). Blaunstain's pathology of the female genital tract, 4th ed. Springer. New York.
20. Kurman R.J. and Trimble C.L. (1993). The behaviour of serous tumors of low malignant potential: are they ever malignant? Int. J. Gynecol. Pathol 12, 120-127.
21. Levine A.J. (1993). The tumor suppressor genes. Annu. Rev. Biochem. 62, 623-651.
22. Mccluggage W.G., Strand K. and Abdulkadir A. (2002). Immunohistochemical localization of metallothionein in benign and malignant ovarian tumors. Int. J. Gynecol. Cancer 12, 62-65.
23. Meplan C., Richard M.J. and Hainaut P. (2000). Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelator in vitro and in intact cells. Oncogene 19, 5227-5236.
24. Miles A.T., Hawksworth G.M., Beattie J.H. and Rodilla V. (2000). Induction, regulation, degradation, and biological significance of mammalian metlothioneins. Crit. Rev. Biochem. Mol. Biol. 35, 35-70.
25. Mocchegianni E., Verbanac D. and Santarelli L. (1997). Zinc and metallothioneins on cellular immune effectiveness during liver regeneration in young and old mice. Life Sci. 61, 1125-1145.
26. Moffatt P. and Denizeau F. Metallothionein in physiological and physiopathological processes. Drug. Metab. Rev. 29, 261-307.
27. 12. Nutrient-Gene Expression, 1688-1694.
28. Riskalla K. and Cherian M. (1997). Metallothionein: a potential marker for differentiating benign and neoplastic gastrointestinal lymphoid infiltrates. Pathology 29, 141-146.
29. Shimoda R., Achanzar W.E., Qu W., Nagamine T., Takagi H., Mori M. and Waalkes M.P. (2003). Metallothionein is a potential negative regulator of apoptosis. Toxicol. Sci. 73, 294-300.
30. Tapiero H. and Tew K.D. (2003). Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed. Pharmacol. 57, 399-411.
31. Tan Y., Sinniah R., Bay B.H. and Singh G. (1999). Metallothionein expression and nuclear size in benign, borderline and malignant serous ovarian tumours. J. Pathol. 189, 60-65.
32. West A.K., Stallings R., Hildebrand C.E., Chiu R., Karin M. and Richards R.I. (1990). Human metallothionein genes: structure of the functional locus at 16q13. Genomics 8, 513-8.
33. Wrigley E., Verspaget H.W., Jayson G.C. and McGown A.T. (2000). J Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. Cancer Res. Clin. Oncol. 126, 717-721.